• Seegene previews a concept video of CURECA^TM at ESCMID Global 2025, ahead of its anticipated debut in July
• With a fully modular design, CURECA^TM introduces a bold vision for automating pre-treatment across diverse PCR specimen types
• Developed for future integration into unattended workflows and adaptable laboratory settings

SEOUL, South Korea, May 2, 2025 /PRNewswire/ — Seegene Inc., a global leader in molecular diagnostics (MDx) solutions, has attracted strong interest after the company presented a conceptual video of its CURECA^TM at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global 2025) in Vienna, Austria. 

YoungSeag Baeg, head of Strategy and Planning at Seegene, briefs customers on CURECA™ on April 14 during ESCMID 2025, held in Vienna, Austria.

Industry professionals recognized CURECA^TM as a promising advancement in automating the entire PCR diagnostic workflow — from primary sample handling to result analysis. In response to the interest received, Seegene provided additional opportunities to showcase the solution at the ESCMID Global 2025.

More than 2,300 attendees — including dignitaries from Italy, Spain, Germany, France, and Canada — visited Seegene’s booth to view the conceptual video introducing the CURECA^TM. “It was evident that the Seegene booth attracted considerable attention at ESCMID,” said one professional from academia.

Experts Recognize CURECA^TM as a Game Changer in Molecular Testing Automation

The CURECA^TM is designed to automate the entire PCR diagnostic process. It can handle various specimen types required in the pre-treatment stage in MDx – such as stool, urine, blood, and sputum—as well as perform the complete PCR testing workflow following sample loading. 

The following are select comments from industry professionals who previewed Seegene’s CURECA^TM at ESCMID Global 2025:

“I hold high expectations for the fully automated PCR molecular diagnostics, as CURECA^TM not only eliminates human error inherent in manual processes but also enables efficient testing without time or workforce constraints.”

“We often encounter specimen types that require careful and time-consuming manual pre-processing. A system that can automate this step could represent a true paradigm shift. This level of automation is transformative – a real game changer – and unlike any existing solution. I eagerly await its launch.”

“If paired with our in-house diagnostic tool kits, CURECA^TM could offer a complete synergy. I hope CURECA^TM will be accessible to small and mid-sized facilities.”

“I’m planning to attend ADLM 2025 in Chicago in July to see the actual device and explore potential collaborations.”

Customizable Pre-Treatment System Offers Versatility for Future Laboratory Automation

The first component of CURECA^TM is the Customizable Pre-treatment System (CPS). The CPS is designed to automate the loading of primary sample tubes and operate pre-treatment processing.

“The CPS is a modular, automated system intended to streamline pre-treatment processing across diverse diagnostic fields including molecular diagnostics such as PCR, as well as clinical chemistry and immunology assays,” said Young-Seag Baeg, Head of Strategy and Planning at Seegene.

Numerous healthcare (or laboratory) professionals at ESCMID Global 2025 noted that the conceptual video of CURECA^TM showcased the potential of fully automated diagnostic laboratories capable of managing complex workflows associated with pre-treatment. In particular, there was consensus among participants that the CPS, which automates specimen preprocessing, is positioned to bring a significant advancement in in vitro diagnostics as it addresses limitations associated with existing manual procedures that are dependent on trained laboratory professionals.

“The turnaround time (TAT) is expected to improve with CURECA^TM as the integrated software is capable of adjusting workflows based on reporting deadlines,” said a director of a laboratory in Spain. “In particular, for sexually transmitted infections (STIs), the CPS will markedly enhance daily laboratory operations. The processing of specimens for STIs involves manual handling of multiple sample tubes, which contributes to operator fatigue. The adoption of the CPS has the potential to be transformational in streamlining routine operations.” 

Modular and Configurable Solution Design for Tailored Diagnostics

Following specimen preprocessing, molecular diagnostics typically involve nucleic acid extraction, PCR setup and amplification, and analysis of results. For specimens that do not need preprocessing, Seegene offers the Primary Sample Aliquot System (PAS) as an alternative to the CPS. PAS is designed to allow direct loading and dispensing of primary samples, helping to simplify the workflow. Seegene is pursuing the integration of PAS with a fully automated PCR process through a modular solution concept called CEFA (Customizable & Expandable Full Automation), intended to support diverse laboratory needs with greater flexibility.

Seegene aims to leverage the modular architecture of CURECA^TM to support a wide range of diagnostic applications. “CURECA^TM can be deployed as a comprehensive system or as individual modules—CPS, PAS, and CEFA—configured independently or in combination to accommodate diverse operational needs,” said Baeg.

Optimizing Lab Workflows Through Space-Saving Design

Another key advantage of the CURECA^TM‘s modular architecture is that it is designed to adapt to different laboratory spaces and layouts. Its flexible design is intended to allow labs to configure the system according to their specific needs, which Seegene sees as essential for enhancing operational efficiency.

Laboratory professionals at ESCMID 2025 shared the following perspectives:

“The ability to configure a system to meet specific spatial and operational needs of individual laboratories represents a novel and highly compelling approach.”

“We expect such flexibility will make it possible to implement workflows that deliver high-quality results with minimal reliance on standardized laboratory configurations and staffing resources.”

“The enthusiastic global response to our concept video and vision for CURECA^TM demonstrate the strong demand for next-generation diagnostic solutions,” said Jong-Yoon Chun, CEO of Seegene. “We believe CURECA^TM has the potential to catalyze meaningful change in the global PCR diagnostics landscape.”

Please Note:

The comments included in this press release are based on actual interviews and on-site discussions. However, in accordance with requests to protect the privacy of the individuals interviewed, all names have been pseudonimized.

About Seegene

Seegene has more than 20 years of dedicated experience in R&D, manufacturing, and business related to syndromic real-time PCR technologies. This expertise was particularly highlighted during the COVID-19 pandemic when Seegene provided over 340 million COVID-19 tests to more than 100 countries worldwide. The core feature of Seegene’s syndromic real-time PCR technology is the ability to simultaneously test for 14 pathogens that cause similar signs and symptoms in a single tube with quantitative information.

Visit: Seegene.com and follow linkedin.com/company/seegene-inc

Technology-sharing Initiative

The technology-sharing initiative aims to globally share Seegene’s advanced diagnostic and data analysis technologies, including syndromic real-time PCR and an automated product development system (SGDDS), with a leading company partnered in each country. Partnering companies will collaborate with local scientists and experts to develop diagnostic tests tailored to the needs of their communities and fields, spanning a wide range of human and non-human diseases. The initiative’s ultimate vision is to create “a world free from diseases”—a future where people no longer suffer from infectious diseases and cancer, and where animals and plants thrive without illness.

Seegene presented a concept video of its CURECA™ system at ESCMID 2025, held April 11–15 in Vienna, Austria.

Seegene’s CURECA™ concept video drew interest from attendees during ESCMID 2025, held April 11–15 in Vienna, Austria.

Photo – https://laotiantimes.com/wp-content/uploads/2025/05/photo_1-1.jpg

Photo – https://laotiantimes.com/wp-content/uploads/2025/05/photo_2_1__seegene_presented_a_concept_video_of_its_cureca__system_at_escmid_2025__held_april_11_15-1.jpg

Photo – https://laotiantimes.com/wp-content/uploads/2025/05/photo_2_2__seegene_s_cureca__concept_video_drew_interest_from_attendees_during_escmid_2025__held_apr-1.jpg

Logo – https://laotiantimes.com/wp-content/uploads/2025/05/seegene_logo_logo-1.jpg

NEW YORK, May 2, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

Kristen Scholer delivers the pre-market update on May 2nd

• Stocks are fractionally higher this morning after the S&P 500 extended its win streak to eight straight sessions on Thursday. The index rose 0.6% as Microsoft and Meta shares rallied after better-than-expected results.
• Overnight, China said its assessing possible trade talks with the U.S. and according to reports, it has started exempting some goods from levies that may cover about a quarter of its impact for the U.S.
• Wall Street turns to April’s Jobs report this morning as forecasters estimate 133,000 jobs were added last month, down from 228,000 in March.

Opening Bell
Ring Magazine celebrates its first-ever boxing event in the United States, titled “FATAL FURY: City of the Wolves” tonight in Times Square.

Closing Bell
Carnival Corporation & plc (NYSE: CCL) counts down the days until it rings in a new tropical island paradise, Celebration Key.

Watch NYSE TV Live every weekday 9:00-10:00am ET

GUANGZHOU, China, May 2, 2025 /PRNewswire/ — Phase 3 of the 137th China Import and Export Fair (Canton Fair), held from May 1 to 5, features 11,759 export exhibitors under the theme “Better Life.” The event sees the shifting dynamics of the global toy industry, emphasizing how Chinese manufacturers are both responding to and shaping the rising demand for toys that appeal not only to children but to consumers of all ages.

Shantou City Chenghai Area Huada Toy Co., Ltd., a veteran in plastic building blocks manufacturing and export, brought a vibrant wall of lifelike flowers to its booth, entirely constructed from plastic building blocks. This creative installation not only turned heads but also highlighted the company’s latest product line, which reimagines building blocks as elegant, display-worthy decor. The featured floral series offers users the satisfaction of hands-on assembly combined with the aesthetic appeal of realistic artificial flowers. Once completed, these pieces can be used as stylish ornaments in homes or offices, bridging the gap between playful creativity and practical design.

“This collection reflects the evolution of toys,” said Chen Xiaowei, the company’s Deputy Marketing Director. “They’re no longer just for children. We’re seeing a growing trend among young adults who enjoy the process of building and the beauty of the finished product.” According to the company, its sub-brand PANLOS is specifically designed with this audience in mind, targeting consumers between 18 and 35.

Meanwhile, Guangdong SYMA Model Aircraft Industrial Co., Ltd drew attention with its latest range of aerial toys, including remote-controlled helicopters, foldable drones, and acrobatic flyers. Equipped with smart sensors and one-touch stunt features, these products provide an accessible entry point for both beginners and seasoned enthusiasts, catering to users of all ages, whether children or adults. Huang Zebin, Chief Marketing Officer of SYMA, emphasized that they consistently launch new products at the Canton Fair. “Given the scale of the event and the diversity of international buyers it attracts, the Fair often brings unexpected opportunities beyond our initial expectations,” he noted.

The rising popularity of “all-age toys” reflects a shift toward more experience-driven, emotionally engaging consumer preferences, prompting companies to rethink traditional product boundaries and uncover new growth opportunities. With a strong focus on advanced design, precision manufacturing, and user-centric innovation, Chinese suppliers are uniquely positioned to lead and scale in this rapidly growing global market.

PHILADELPHIA, May 2, 2025 /PRNewswire/ — Darnatein, a subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH), a biotechnology company advancing design-augmented biologics, announced today that it will present scientific data at the 14th International Bone Morphogenetic Protein (BMP) Conference, taking place May 2–6, 2025, at the University of Pennsylvania in Philadelphia.

The BMP Conference brings together leading global researchers to explore the latest breakthroughs in BMP-related biology and regenerative medicine. This year’s program highlights novel technologies and fundamental research in tissue and organ regeneration. (https://www.14thbmpconference2025.com/)

Dr. Senyon “Teddy” Choe, CEO of Darnatein, will deliver a scientific presentation on May 3, titled:
“Design-Augmented Synthetic BMP Chimeras as Super-Agonists for Bone and Cartilage Regeneration.”

The presentation will showcase Darnatein’s proprietary platform technology that has led to the development of DRT-101 and DRT-102, two novel biologic candidates engineered to function as BMP super-agonists. DRT-101 with good preclinical safety profiles is being developed for joint cartilage regeneration, while DRT-102 is focused on spinal bone repair.

“This presentation reflects Darnatein’s growing leadership in synthetic regenerative biologics,” said Dr. Choe. “Our DA Biologics platform is enabling the creation of highly potent, next-generation growth factors with potential to transform musculoskeletal repair.”

Darnatein’s participation at the BMP Conference underscores a year of significant progress, including:

• Preclinical validation of DRT-101 and DRT-102 demonstrating safety and enhanced regeneration of cartilage and bone tissue.
• Ongoing IND-enabling studies in collaboration with BioToxTech, a publicly-listed CRO based in South Korea and the University of California, San Diego, aimed at advancing DRT-101 toward IND submissions with the Korean MFDS and U.S. FDA.

The company remains committed to expanding its Design-Augmented Biologics platform to address unmet needs in regenerative medicine globally.

About Darnatein

Darnatein is a biotechnology subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH) focused on the development of design-augmented biologics for regenerative medicine. The company’s proprietary platform harnesses synthetic biology and protein engineering to create next-generation growth factors for musculoskeletal and tissue repair. Lead candidates DRT-101 and DRT-102 are being developed for joint cartilage and spinal bone regeneration, respectively.

About OSR Holdings

OSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families. OSR aims to build and develop a robust portfolio of innovative and potentially transformative therapies and healthcare solutions. Its current operating businesses (through three wholly-owned subsidiaries) include (i) developing oral immunotherapies for the treatment of cancer (“Vaximm”), (ii) developing design-augmented biologics for age-related and other degenerative diseases (“Darnatein”) and (iii) neurovascular intervention medical device and systems distribution in Korea (“RMC”).  OSR’s vision is to acquire and operate a portfolio of innovative healthcare related companies globally.

Contact:
ir@osr-holdings.com

KUALA LUMPUR, Malaysia, May 2, 2025 /PRNewswire/ — As Southeast Asia’s pharmaceutical industry rapidly evolves—driven by regulatory harmonization, innovation, and growing healthcare demand—CPHI South East Asia 2025 provides a vital platform to connect with regional stakeholders, showcase breakthroughs, and unlock business opportunities across the ASEAN region.

Taking place for the first time in Kuala Lumpur, Malaysia, from 16–18 July 2025, the event will bring together 8,000+ professionals, 400+ global exhibitors, and curated buyers from across Asia and beyond—positioning it as the region’s most impactful pharma event.

Unlock Growth Across ASEAN’s Pharma Markets

From Indonesia, Thailand, Vietnam, the Philippines to Malaysia, Southeast Asia is one of the world’s most dynamic pharmaceutical regions. Governments are investing in local manufacturing, reforming regulatory systems, and opening doors to international partnerships.

Malaysia, as this year’s host, plays a central role in this growth. ^[1]The country’s pharmaceutical market is expected to rise from RM11.2 billion in 2022 to RM15.5 billion by 2027, supported by the New Industrial Master Plan (NIMP) 2030, which incentivizes the production of APIs, biologics, and vaccines.

^[2] Strategically located between Singapore and Indonesia, Malaysia offers streamlined access to regional distributors, CDMOs, and packaging partners—making Kuala Lumpur a strategic gateway to ASEAN-wide expansion.

At CPHI South East Asia 2025, you’ll be able to:

• Access to high-growth markets across ASEAN with strong government backing for international pharma collaboration
• First-mover advantage in a fresh, opportunity-rich environment
• Direct connections with regional buyers, distributors, and contract manufacturers
• Connect through strategic matchmaking with pre-qualified buyers from across ASEAN.

Event Highlights

• Innovation Showcase
  Discover a broad spectrum of pharmaceutical innovations—from APIs, generic APIs, and excipients to biopharmaceuticals, herbal medicine, natural extracts, and finished dosage formulations. Explore the latest in custom manufacturing, drug delivery systems, pharma packaging, analytical & lab equipment, and pharmaceutical machinery & technology—all in one place.
• Conference
  Hear from regulators, manufacturers, and experts on key topics including clinical trials, regulatory harmonization, and ASEAN market access.
• Match & Meet (Business Matching Program)
  Connect through pre-arranged meetings with verified buyers actively sourcing products and partnerships.
• Special Zones & Activities
  Discover immersive experiences and dedicated features including the International Pavilions, Sustainability Square, Pharma Quest (Competition), and more—designed to foster innovation, education, and cross-border collaboration.

Venue: MITEC, Kuala Lumpur
Dates: 16–18 July 2025
Explore more at:  https://www.cphi.com/sea

Register to visit at:  https://cphisea.imasia-passport.com/